[go: up one dir, main page]

AR093118A1 - Composiciones y metodos para la administracion transdermica de anfetamina - Google Patents

Composiciones y metodos para la administracion transdermica de anfetamina

Info

Publication number
AR093118A1
AR093118A1 ARP130103858A ARP130103858A AR093118A1 AR 093118 A1 AR093118 A1 AR 093118A1 AR P130103858 A ARP130103858 A AR P130103858A AR P130103858 A ARP130103858 A AR P130103858A AR 093118 A1 AR093118 A1 AR 093118A1
Authority
AR
Argentina
Prior art keywords
compositions
amphetamine
methods
transdermal administration
film
Prior art date
Application number
ARP130103858A
Other languages
English (en)
Inventor
L Lambert Robert
Original Assignee
Noven Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noven Pharma filed Critical Noven Pharma
Publication of AR093118A1 publication Critical patent/AR093118A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones para administrar anfetaminas por vía transdérmica que toman la forma de sistemas finitos flexibles. Estas composiciones comprenden una matriz polimérica, que comprende una anfetamina o una sal o una prodroga farmacéuticamente aceptable de ésta, y una capa de respaldo, que comprende una capa de poliuretano en forma de película y una capa de poliéster en forma de película, con un adhesivo a base de poliuretano entre ellas. Métodos relacionados con dichas composiciones. Composiciones que presentan un período de inicio breve y que dan como resultado un efecto terapéutico prolongado.
ARP130103858A 2012-10-25 2013-10-24 Composiciones y metodos para la administracion transdermica de anfetamina AR093118A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261718537P 2012-10-25 2012-10-25
US201361791018P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR093118A1 true AR093118A1 (es) 2015-05-20

Family

ID=49546636

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103858A AR093118A1 (es) 2012-10-25 2013-10-24 Composiciones y metodos para la administracion transdermica de anfetamina

Country Status (9)

Country Link
US (5) US9474722B2 (es)
EP (1) EP2934496B1 (es)
JP (1) JP2015535253A (es)
AR (1) AR093118A1 (es)
CA (1) CA2889452C (es)
ES (1) ES2621915T3 (es)
HK (1) HK1216503A1 (es)
TW (1) TWI632923B (es)
WO (1) WO2014066585A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889452C (en) 2012-10-25 2016-09-13 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine
MX366230B (es) 2012-12-28 2019-07-03 Noven Pharma Composiciones multipolimericas para liberación transdermica de farmaco.
WO2014106014A1 (en) 2012-12-28 2014-07-03 Noven Pharmaceuticals, Inc Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol
WO2014159582A1 (en) 2013-03-14 2014-10-02 Noven Pharmaceuticals, Inc Amphetamine transdermal compositions with acrylic block copolymer
AR095260A1 (es) * 2013-03-15 2015-09-30 Noven Pharma Composiciones de anfetaminas transdérmicas estables y métodos de fabricación
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
ES2687344T3 (es) * 2013-12-23 2018-10-24 Noven Pharmaceuticals, Inc. Composiciones y métodos para la administración transdérmica de anfetamina
AR101358A1 (es) 2014-07-31 2016-12-14 Noven Pharma Composiciones de polímeros acrílicos que contienen siliconas para la administración transdérmica de fármacos
US20190298661A1 (en) * 2016-10-31 2019-10-03 The Corporation Of Mercer University Transdermal Delivery of Phenethylamine Monoamine Releasers
CN117529665A (zh) 2021-01-07 2024-02-06 诺芬药品公司 安非他命氨基甲酸盐化合物和方法
AR124577A1 (es) 2021-01-07 2023-04-12 Noven Pharma Composiciones transdérmicas de anfetamina con bajos niveles de carbamato

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994278A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US20030170195A1 (en) * 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
AU3932600A (en) 1999-04-01 2000-10-23 Alza Corporation Transdermal drug delivery devices comprising a polyurethane drug reservoir
CA2427388C (en) * 2000-11-01 2011-12-20 Sention, Inc. Pharmaceutical compositions and uses for improving memory and learning impairments
WO2004052612A1 (ja) * 2002-12-10 2004-06-24 Mitsubishi Rayon Co., Ltd. ベルト式連続製板装置および板状重合物の製造方法
RU2356580C2 (ru) 2003-10-28 2009-05-27 Новен Фармасьютикалз, Инк Композиции и способы, обеспечивающие контролируемую потерю лекарственных средств и доставку в системах трансдермальной доставки лекарственных средств
WO2006041907A2 (en) * 2004-10-08 2006-04-20 Noven Pharmaceuticals, Inc. Transdermal delivery of estradiol
TW200628175A (en) 2004-10-08 2006-08-16 Noven Pharma Transdermal drug delivert device including an occlusive backing
WO2007100777A2 (en) * 2006-02-28 2007-09-07 The Mclean Hospital Corporation Methods for the treatment of adhd and related disorders
US20080220054A1 (en) * 2006-10-13 2008-09-11 Shastri V Prasad Modulation of drug release rate from electrospun fibers
JP2008104547A (ja) 2006-10-24 2008-05-08 Aruze Corp 遊技機及び遊技システム
AU2009353789A1 (en) 2009-10-07 2012-08-02 Venkata Surya Jagannath Yedida Transdermal therapeutic system
US20130015092A1 (en) * 2011-07-14 2013-01-17 Nitto Denko Corporation Patch package
CA2889452C (en) 2012-10-25 2016-09-13 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine
US20150104495A1 (en) 2012-10-25 2015-04-16 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine
WO2014159582A1 (en) 2013-03-14 2014-10-02 Noven Pharmaceuticals, Inc Amphetamine transdermal compositions with acrylic block copolymer
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria

Also Published As

Publication number Publication date
ES2621915T3 (es) 2017-07-05
US10004696B2 (en) 2018-06-26
US9456993B2 (en) 2016-10-04
US20150119828A1 (en) 2015-04-30
EP2934496B1 (en) 2017-03-15
WO2014066585A1 (en) 2014-05-01
TWI632923B (zh) 2018-08-21
US20170246126A1 (en) 2017-08-31
US20180243242A1 (en) 2018-08-30
US20170181980A1 (en) 2017-06-29
CA2889452A1 (en) 2014-05-01
US20140121611A1 (en) 2014-05-01
HK1216503A1 (zh) 2016-11-18
TW201427723A (zh) 2014-07-16
CA2889452C (en) 2016-09-13
US9474722B2 (en) 2016-10-25
JP2015535253A (ja) 2015-12-10
US9901552B2 (en) 2018-02-27
EP2934496A1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
AR093118A1 (es) Composiciones y metodos para la administracion transdermica de anfetamina
CY1126136T1 (el) Μεθοδοι θεραπειας της αρθριτιδας
CR20150360A (es) Sistema de liberación transdérmica
MX382516B (es) Composiciones y metodos para absorcion transmucosa.
CL2014001450A1 (es) Forma de dosis de liberacion controlada solida que comprende un analgesico opioide dispersado en un material de matriz; metodo de preparacion; uso en el tratamiento del dolor.
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
MX2013002207A (es) Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
PE20120371A1 (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak
AR084691A1 (es) Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
MX2018000166A (es) Metodos para una mejor administración de agentes activos a tumores.
CL2014002464A1 (es) Método para mejorar la eficacia de una transfusión de sangre que comprende la administración de una proteína sanguínea pegilada; oligómero de proteína sanguínea pegilada; proteína sanguínea pegilada; y composición que la comprende.
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
MX385833B (es) Derivados de n-acildipeptido y sus usos.
EP2589379A4 (en) TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DEPPEZIL
MY183873A (en) Transdermal therapeutic system for application of an agent
CL2015000289A1 (es) Compuesto citostatico derivado de niclosamida y compuesto alquilante derivado de 2,3,4,6,8-pentazabiciclo[4.3.0]nona-2,7-trieno; composicion farmaceutica que los comprende; y metodo para determinar si el tratamiento para un paciente con un tumor solido es adecuado.
EA201400628A1 (ru) Трансдермальная терапевтическая система для введения фентанила или его аналога
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
CO6440534A2 (es) Composiciones y métodos para terapia prolongada con aminopiridinas
MX384311B (es) Combinación con minicélulas dirigidas por ligando, biespecíficas, cargadas con fármacos e interferón-gamma para usarse en el tratamiento de tumores.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.

Legal Events

Date Code Title Description
FB Suspension of granting procedure